Organ-on-a-Chip Resources

Organ-on-a-chip Contract Research Services Brochure

Discover our full range of Organ-on-a-chip contract research services including ADME, NASH, DILI and Oncology as well as all the relevant endpoints.

A primary jejunum and primary hepatocyte multi-organ MPS

Find out how our gut-liver MPS recapitulates the physiological condition enabling oral drug dosing in vitro. This gut-liver model offers a vast improvement in the methods used to study PK or prodrugs.

ADME Studies: Determining Promising Drug Compounds

Dr Abbas discusses factors that can affect the outcome of an ADME study, signs that a drug compound shows promise, red flags, and key parameters to determine safety and efficacy.

This article is taken from PharmTech, November 2022.

How to Keep Breathing – The Future of Inhaled Medication Testing

Dr Emily Richardson discusses the current challenges faced to bring inhaled therapeutics to the market and the potential of Organ-on-a-Chip to increase positive outcome by improving ADME drug testing.

This article is taken from International Biopharmaceutical Industry, Summer 2022.

PhysioMimix Multi-organ System Animation

An introduction to the CN Bio PhysioMimix Multi-organ System. This animation demonstrates how our microphysiological system works, how to create a Gut/Liver-on-a-chip model and an example of its use.

Application of a gut–liver-on-a-chip device and mechanistic modeling to the quantitative in vitro pharmacokinetic study of mycophenolate mofetil

Milani et al., 2022

This study shows how an in vitro gut-liver multi-organ model can quantitatively recapitulate the in vivo metabolism of a drug. By combining Organ-on-a-chip with in silico modeling, the study also demonstrates the potential of multi-organ models for quantitative estimation of PK parameters of a drug and its metabolites.

Every Breath You Take

Webinar Series 5 Episode 2

In this webinar, Lead Scientist, Dr Emily Richardson describes novel alveolar and bronchial lung-on-a-chip, or lung MPS, models. She demonstrates how to predict drug pharmacokinetics, allowing for more rapid, precise, and cost-effective compound analysis.

Why two organs are better than one

Abbas, Kostrzewski & Hughes

This poster demonstrates how a gut-liver MPS can improve oral bioavailability predictions by mimicking human oral and IV regimens. Thus improving the in vitro to in vivo translation of drug efficacy and safety.

A microfluidic system that replicates pharmacokinetic (PK) profiles in vitro improves prediction of in vivo efficacy in preclinical models

Singh et al., 2022

This publication demonstrates the Microformulators capability to incorporate replicated PK exposures into cellular assays to improve in vitro–in vivo translation understanding. This is demonstrated through comparisons to traditional fixed dose in vitro studies and in vivo xenograft models.

Normalization of organ-on-a-chip samples for mass spectrometry based proteomics and metabolomics via dansylation-based assay

Gallagher et al

This poster shows the combined use of MS-based proteomics and metabolomics with organ-on-a-chip to better assess the classification of biological replicates in toxicity studies.

Harnessing the power of multimodal imaging to explore ASO distribution in cells, complex in vitro models and tissue

Alex et al

This recent poster from GSK and collaborators features data from our PhysioMimix® OOC and Liver (MPS-LC12) plates. The results demonstrate that the distribution of ASOs into Kupffer cells and circular or cuboidal hepatocytes cultured in 3D can be detected using imaging.

Bridging Gaps in Translational Biology

Petreus et al

Developing effective oncology therapies involves defining the right schedules to minimize side effects and maximise efficacy. This requires an accurate understanding of the pharmacokinetic/pharmacodynamics PK/PD relationship of the compound(s). Animal and human PKs can differ significantly and many failures of novel therapies are due to a missing physiologically relevant link between preclinical and clinical data.​